Multiple Myeloma Hub | Quarter Two 2020 Update

In the second quarter of 2020, the Multiple Myeloma Hub launched its brand-new website. The hub has been redesigned to facilitate navigation, allowing users to filter by disease subtypes, therapeutics, congresses, trials, and expert opinions. A new feature on the website is the podcast channel. Podcasts are available on Apple Podcast, Spotify, and all other major podcast apps to listen to and download. The updated platform further enables the Multiple Myeloma Hub to disseminate the latest clinical updates in multiple myeloma (MM).

In April, the Multiple Myeloma Hub covered the American Association for Cancer Research (AACR) Annual Meeting via the social media channels and provided summaries of key sessions.

In May, the Multiple Myeloma Hub held a virtual Steering Committee meeting. The hub was also in virtual attendance at the Controversies in Multiple Myeloma (COMy) Online Meeting and the American Society of Clinical Oncology (ASCO) Annual Meeting, providing live session coverage and hosting interviews with leaders in the myeloma field. The Multiple Myeloma Hub also presented a new editorial theme, ‘Monoclonal antibodies for the treatment of MM’.

In June, we provided live coverage of key sessions from the 25th European Hematology Association (EHA25) Annual Congress and produced podcasts and expert interviews.

The Multiple Myeloma Hub showcases unbiased and credible evidence-based literature, drug approvals, case studies, international congress coverage, and expert opinions, and is brought to you by Scientific Education Support (SES). SES strives to build communities and networks to enhance the level of collective knowledge, using multichannel communications to disseminate medical advances.

Guided by an international Steering Committee of world experts, and run in collaboration with the European School of Haematology (ESH), the Multiple Myeloma Hub is a global online resource that provides vital information for treatment teams, including hematologists and oncologists. Our mission is to provide up-to-date, practical, and clinical advice to community hematologists and oncologists, and ensure patients with MM have access to the latest therapies available.

The Multiple Myeloma Hub would like to thank its Silver supporter GSK, Bronze supporter Amgen, and contributor level supporter Karyopharm Therapeutics for their continued support.

For further information on the Multiple Myeloma Hub, please visit multiplemyelomahub.com/. For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com.